Evidence map›Paper›PMID 33170519›Full record

ArticleJournal of the American Geriatrics Society2021

FGF23 and Cause-Specific Mortality in Community-Living Individuals-The Health, Aging, and Body Composition Study.

Shilpa Sharma, Ronit Katz, Ruth F Dubin, David A Drew, Orlando M Gutierrez, Michael G Shlipak, Mark J Sarnak, Joachim H Ix

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of the American Geriatrics Society, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
1.0field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it, 12 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Review
  6. Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 6 institutions in 1 country.

Shilpa SharmaDivision of Nephrology, David Geffen School of Medicine at UCLA and VA Greater Los Angeles Healthcare System, Los Angeles, California, USA.ORCID 0000-0001-9011-0163
Ronit KatzDepartment of Obstetrics and Gynecology, University of Washington, Seattle, Washington, USA.
Ruth F DubinKidney Health Research Collaborative, University of California San Francisco, San Francisco, California, USA.
David A DrewDivision of Nephrology, Department of Medicine, Tufts Medical Center, Boston, Massachusetts, USA.ORCID 0000-0003-0377-723X
Orlando M GutierrezDepartments of Medicine and Epidemiology, University of Alabama at Birmingham, Birmingham, Alabama, USA.
Michael G ShlipakKidney Health Research Collaborative, University of California San Francisco, San Francisco, California, USA.
Mark J SarnakDivision of Nephrology, Department of Medicine, Tufts Medical Center, Boston, Massachusetts, USA.
Joachim H IxDivision of Nephrology-Hypertension, University of California San Diego and Veteran Affairs San Diego Healthcare System, San Diego, California, USA.
Tufts Medical Center · USUniversity of California, San Francisco · USUniversity of Alabama at Birmingham · USUniversity of California San Diego · USUniversity of Washington · USVA Greater Los Angeles Healthcare System · US

Funding

University of Alabama at Birmingham's Diabetes Research CenterP30DK079626 · NIDDK · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI BARBARA A GOWER · 2013 to 2026
$19.5M
The Aging Kidney: Chronic Injury, Impaired Functions and Clinical OutcomesR01AG027002 · NIA · TUFTS MEDICAL CENTER · PI PARIKH, SAMIR M, SARNAK, MARK J · 2005 to 2022
$7.3M
The association of FGF-23 and Klotho with cognitive impairment and cerebrovascular disease in chronic kidney diseaseK23DK105327 · NIDDK · TUFTS MEDICAL CENTER · PI DREW, DAVID ALAN · 2016 to 2020
$958k
Mentored Patient Oriented Research in Kidney DiseaseK24DK110427 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI IX, JOACHIM H · 2016 to 2020
$780k
NIA NIH HHS R01 AG027002NIA NIH HHS R01AG027002NIDDK NIH HHS K23 DK105327NIDDK NIH HHS K24 DK110427NIDDK NIH HHS P30 DK079626
6 · The paper itself

Abstract

objectivesFibroblast growth factor (FGF)-23 is a key regulator of mineral metabolism and has been linked with left ventricular hypertrophy in animal models. Most existing epidemiologic studies evaluated a C-terminal FGF23 assay which measures both the intact (active) hormone and inactive fragments. The relationship of intact FGF23 with cause-specific mortality is unknown.

designProspective analyses of data from Health, Aging, & Body Composition (HABC) study.

settingCommunity-living adults aged 70 to 79 years with longitudinal follow up.

Indexed as

Cause of DeathAgedAgingBiomarkersCardiovascular DiseasesFemaleFibroblast Growth Factor-23Fibroblast Growth FactorsHumansIndependent LivingMaleProspective StudiesBiomarkersFGF23 protein, humanFibroblast Growth Factor-23Fibroblast Growth Factorsassayscause-specificFGF23mortality

Identifiers

PMID33170519
PMCPMC8175094
OpenAlexW3101128955

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.